Vitiligo

Clinuvel has commenced its INSPIRE (International SCENESSE® Pilot Repigmentation Evaluation) program to evaluate the use of its first-in-class drug SCENESSE® (afamelanotide) as a repigmentation therapy in vitiligo.

The first of these studies, CUV102, has completed, with treatment results released in December 2012.

Clinuvel has established this webpage to serve as a portal for all information relevant to this study and vitiligo more broadly. See this document for more details on participating in the INSPIRE program.

Vitiligo Blog Posts

In what has become something of a tradition in recent years, yet another country has used the new year to adopt further laws related to...

Read More

Vitiligo Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now